Clinical trialPhase 1Completed
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 9 December 2022
- Expected end
- 12 May 2025
- Enrollment
- 70 participants
- Sites
- 35
- Primary outcomes
- Number of participants with Adverse Events (AEs); Number of participants with Serious Adverse Events (SAEs); Number of participants with Dose-Limiting Toxicities (DLTs); Number of participants with AEs leading to discontinuation; Number of deaths
- Sponsor
- Industry
- Results posted
- No
- Last update
- 13 June 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.